Skip to content

Study on the Relationship between Plasma Heat Shock Protein 90a Levels and Treatment Efficacy in Bladder Cancer Patients

Study on the Correlation between Plasma HSP90a Levels and Treatment Prognosis in Bladder Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124559
Enrollment
Unknown
Registered
2026-05-13
Start date
2025-12-02
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carcinoma of urinary bladder

Interventions

Patients with bladder cancer VS healthy volunteers:None

Sponsors

Harbin Medical University Affiliated Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.The patient was diagnosed with bladder cancer by pathology. This was a patient whose HSP90a level was measured before the first treatment. The patient or their family fully understood the purpose, methods, risks, and benefits of this study, and were willing to cooperate with all the examinations and follow-up work during the research process.

Exclusion criteria

Exclusion criteria: 1.Combining other malignant tumors except for bladder cancer to avoid interference from other tumors on the plasma HSP90a level and prognosis. Patients with severe cardiovascular and cerebrovascular diseases (such as acute myocardial infarction, extensive cerebral infarction, severe cardiac insufficiency, etc.), and liver and kidney dysfunction (such as end-stage renal disease, decompensated liver cirrhosis, etc.) may affect the patient's survival and plasma indicators, thereby interfering with the research results.Presence of infectious diseases (such as severe sepsis, active pulmonary tuberculosis, etc.) and autoimmune diseases (such as systemic lupus erythematosus, active rheumatoid arthritis, etc.)

Design outcomes

Primary

MeasureTime frame
hsp90a level;

Countries

China

Contacts

Public ContactLiu Duo

Harbin Medical University Affiliated Cancer Hospital

liuduo95@126.com+86 451 86298399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026